Annual report pursuant to Section 13 and 15(d)

Reorganization and Recapitalization (Details) - Schedule of purchase price consideration paid to accounting acquirees

v3.21.2
Reorganization and Recapitalization (Details) - Schedule of purchase price consideration paid to accounting acquirees
 12 Months Ended
Dec. 31, 2020
USD ($)
Business Acquisition [Line Items]  
Debt assumed $ 270,000
Shares at fair value 45,866,498
Total Purchase Consideration 46,136,498
CBR Pharma [Member]  
Business Acquisition [Line Items]  
Debt assumed
Shares at fair value 24,927,274
Total Purchase Consideration 24,927,274
180 LP [Member]  
Business Acquisition [Line Items]  
Debt assumed 270,000
Shares at fair value 20,939,224
Total Purchase Consideration $ 21,209,224